Why Amgen’s 6% Dividend Raise Masks a Tougher Road Ahead
Amgen just handed income investors another dividend raise, but a mountain of acquisition debt, crumbling legacy drugs, and a billion-dollar obesity bet are all competing for the same pool of cash.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Amgen (NASDAQ:AMGN | AMGN Price Prediction) pays $2.52 per share quarterly, an annualized rate of $10.08. Its first payout in August 2011 was $0.28. With shares at $418.13 and up 30.36% year to date, income investors need to know whether the cash engine can sustain raises while taking on biosimilar losses and an expensive obesity program.
A Biotech That Raises Like a Utility
Amgen raises its dividend annually in steady steps. The latest lifted the quarterly payout from $2.38 to $2.52, a 6% increase matching the prior year. Dividend cash rose from $3.509 billion in 2019 to $5.124 billion in 2025.
“In addition, we return capital to shareholders through competitive dividend payments of $2.52 per share, representing a 6% increase compared to the second quarter of 2025.”
That rhythm matches Johnson & Johnson (NYSE:JNJ), a Dividend King. Pfizer (NYSE:PFE) offers higher yield but has struggled with payout coverage post-COVID. Amgen yields 2.36%, compressed by the stock’s rally.
Coverage Looks Solid, but Debt Sets the Speed Limit
Amgen generated $8.1 billion in free cash flow in 2025 against $5.124 billion in dividends paid. In the second quarter of 2026, free cash flow reached $3.5 billion while dividends consumed $1.362 billion. Management guides 2026 non-GAAP EPS to $22.30 to $23.50, far above the $10.08 forward dividend, and trailing GAAP EPS of $16.22 also covers it.
The balance sheet limits growth. Total debt stood at $57.304 billion at June-end against $13.989 billion in cash, largely from the Horizon Therapeutics acquisition. Interest expense ran $2.755 billion in 2025. Amgen limited 2026 buybacks at $3.0 billion, focusing on the dividend and debt paydown.
“That sound financial structure also gives us the flexibility to invest with discipline in both our internal pipeline and external innovation while supporting the long-term needs of the business.”
Biosimilars and MariTide Will Decide Future Raises
Mature franchises are declining. Prolia and XGEVA combined for $1.1 billion in second-quarter sales, down 33%. Enbrel fell 37% in the first quarter as Medicare Part D price setting took effect, and Otezla’s IRA selection triggered a $1.2 billion impairment.
MariTide is the swing factor. Amgen has nine Phase 3 studies running and three more planned, with full-year non-GAAP R&D growing high single digits. It is the largest pipeline opportunity and the biggest competitor to the dividend for cash.
“As I’ve said before, the bar is high at Amgen for obesity medicines.”
“Our first quarter results demonstrate the strength of our business, with 16 brands achieving double-digit growth, enabling us to grow through expected patent expirations and increased competition.”
Verdict: The Raises Keep Coming at a Measured Pace
Amgen’s dividend is safe. Free cash flow covers the payout comfortably, earnings guidance sits far above the forward rate, and buybacks rank behind the dividend. The debt load keeps raises in the mid-single digits. Watch MariTide Phase 3 data and Prolia erosion, as those variables set the size of each future raise.
Contact [email protected] for any questions or corrections.
Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.
His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.
When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.
